119 related articles for article (PubMed ID: 25676033)
1. Serum soluble LR11, a novel tumor derived biomarker associated with the outcome of patients with diffuse large B-cell lymphoma.
Ohwada C; Yamazaki A; Kawaguchi T; Sugita Y; Takeuchi M; Shimizu N; Sakaida E; Takeda Y; Tsukamoto S; Muto T; Jiang M; Higashi M; Yokote K; Tamaru J; Bujo H; Nakaseko C
Leuk Lymphoma; 2015; 56(10):2982-5. PubMed ID: 25676033
[No Abstract] [Full Text] [Related]
2. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis.
Sugita Y; Ohwada C; Kawaguchi T; Muto T; Tsukamoto S; Takeda Y; Mimura N; Takeuchi M; Sakaida E; Shimizu N; Tanaka H; Abe D; Fukazawa M; Sugawara T; Aotsuka N; Nishiwaki K; Shono K; Ebinuma H; Fujimura K; Bujo H; Yokote K; Nakaseko C
Clin Chim Acta; 2016 Dec; 463():47-52. PubMed ID: 27725222
[TBL] [Abstract][Full Text] [Related]
3. Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma.
Kawaguchi T; Ohwada C; Takeuchi M; Shimizu N; Sakaida E; Takeda Y; Sakai S; Tsukamoto S; Yamazaki A; Sugita Y; Higashi M; Fujikawa K; Matsue K; Yokote K; Tamaru J; Bujo H; Nakaseko C
Leuk Lymphoma; 2014 Oct; 55(10):2391-4. PubMed ID: 24401112
[No Abstract] [Full Text] [Related]
4. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
Fujimura K; Ebinuma H; Fukamachi I; Ohwada C; Kawaguchi T; Shimizu N; Takeuchi M; Sakaida E; Jiang M; Nakaseko C; Bujo H
Clin Chim Acta; 2014 Mar; 430():48-54. PubMed ID: 24394293
[TBL] [Abstract][Full Text] [Related]
5. BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Papageorgiou SG; Kontos CK; Foukas PG; Panopoulou E; Vasilatou D; Rapti SM; Gkontopoulos K; Bazani E; Panayiotides IG; Dimitriadis G; Scorilas A; Pappa V
Leuk Lymphoma; 2016 Sep; 57(9):2199-203. PubMed ID: 27442703
[No Abstract] [Full Text] [Related]
6. Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
Öztürk E; Özbalak M; Berk S; Erdoğan I; Avşar E; Dolgun A; Çetiner M; Mandel NM; Yalnız FF; Elverdi T; Salihoğlu A; Eşkazan AE; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T; Ferhanoğlu B
Leuk Lymphoma; 2016 May; 57(5):1211-4. PubMed ID: 26294270
[No Abstract] [Full Text] [Related]
7. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
8. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma.
Eatrides J; Thompson Z; Lee JH; Bello C; Dalia S
Ann Hematol; 2015 Feb; 94(2):357-8. PubMed ID: 25034876
[No Abstract] [Full Text] [Related]
9. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
10. The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
Tomita N; Suzuki T; Miyashita K; Yamamoto W; Motohashi K; Tachibana T; Takasaki H; Kawasaki R; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Taguchi J; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Motomura S; Kawamoto K; Sone H; Takizawa J
Leuk Lymphoma; 2016 Dec; 57(12):2763-2770. PubMed ID: 27320054
[TBL] [Abstract][Full Text] [Related]
11. Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.
Pauly F; Fjordén K; Leppä S; Holte H; Björkholm M; Fluge Ø; Møller Pedersen L; Eriksson M; Isinger-Ekstrand A; Borrebaeck CA; Jerkeman M; Wingren C
Blood Cancer J; 2016 Nov; 6(11):e501. PubMed ID: 27858932
[No Abstract] [Full Text] [Related]
12. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
13. A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Sawada T; Omuro Y; Hishima T; Maeda Y
Leuk Lymphoma; 2016 Oct; 57(10):2460-3. PubMed ID: 26886828
[No Abstract] [Full Text] [Related]
14. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.
Jardin F; Delfau-Larue MH; Molina TJ; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Jais JP; Figeac M; Leroy K; Mareschal S; Salles GA; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Haioun C; Tilly H
Leuk Lymphoma; 2013 Sep; 54(9):1898-907. PubMed ID: 23327290
[TBL] [Abstract][Full Text] [Related]
15. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
16. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.
Sakai S; Nakaseko C; Takeuchi M; Ohwada C; Shimizu N; Tsukamoto S; Kawaguchi T; Jiang M; Sato Y; Ebinuma H; Yokote K; Iwama A; Fukamachi I; Schneider WJ; Saito Y; Bujo H
Clin Chim Acta; 2012 Oct; 413(19-20):1542-8. PubMed ID: 22750733
[TBL] [Abstract][Full Text] [Related]
17. Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
Green TM; Jensen AK; Holst R; Falgreen S; Bøgsted M; de Stricker K; Plesner T; Mourits-Andersen T; Frederiksen M; Johnsen HE; Pedersen LM; Møller MB
Br J Haematol; 2016 Sep; 174(6):876-86. PubMed ID: 27196819
[TBL] [Abstract][Full Text] [Related]
18. [Novel biomarker for pathological immature cells--soluble form of LR11].
Bujo H
Rinsho Byori; 2012 May; 60(5):469-76. PubMed ID: 22774576
[TBL] [Abstract][Full Text] [Related]
19. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Yamada T; Sawada M; Takahashi T; Yamada T; Seishima M; Moriwaki H; Takami T
Leuk Lymphoma; 2012 Aug; 53(8):1494-500. PubMed ID: 22280534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
